Antares Pharma, Inc. (ATRS)

[H2R]

Nice find Rymankoly!

From the company presentation (slide 16):

* AMAG/Makena alliance started in 2014
* Makena 2016 revenue was ~$334M, expected to grow to ~$410-$440M in 2017
* Positive top line 2/2/2017
* AMAG estimates sNDA filing 2Q17 (given your link, they are on schedule :)
* ATRS will supply devices at a reasonable margin plus receive high single to low double digit royalties and sales milestones.

From your link:

AMAG developed the Makena auto-injector with its device partner Antares Pharma, Inc., (NASDAQ:ATRS) which holds issued patents on the auto-injector. If the Makena auto-injector is approved, AMAG will request Orange Book listing of the eligible Antares patents, the last of which expires in 2026.